arrow
M

Mehmet Altan

the university of texas-md anderson cancer center
H指数:40
被引数:7,334

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study

恩沃利单抗联合帕博利珠单抗治疗尿路上皮癌患者肺炎的发生率及危险因素:回顾性研究

2026-09-170
OAAI
Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center

使用诱导化免疗法作为非转移性NSCLC患者接受根治性局部治疗的桥梁:来自综合癌症中心的真实世界结果

2026-09-010
PRE
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC

PADL1NK-005研究设计:一项关于fetranstobart vedotin(Fetra-V)与多西他赛治疗既往经治PD-L1阳性非小细胞肺癌患者的III期临床试验

2026-01-010
OAAI
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS

多机构关于tarlatamab给药及CRS/ICANS管理的观点

2025-12-060
PRE
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

MET过表达与晚期非小细胞肺癌中更优的免疫治疗效果相关联

2025-11-270
OAAI
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study

曲妥珠单抗德鲁克替康(trastuzumab Deruxtecan)引起的肺炎发生率和风险因素:一项回顾性队列研究

2025-11-050
OAAI
Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples

基于成像的单细胞分辨率空间转录组学分析平台比较:使用福尔马林固定石蜡包埋肿瘤样本

2025-09-260
OAAI
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

机器学习驱动的转移性非小细胞肺癌免疫治疗适应性策略

2025-07-240
OAAI
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma

与检查点抑制剂相关的肺炎在复发或难治性淋巴瘤中的发生率和危险因素

2025-05-160
PRE
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model

利用Brock模型和Sybil模型对持续性肺结节患者进行肺癌风险评估

CANCERS
IF4.4
2025-04-290
OA
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report

达拉他单抗在未经治疗的SCLC脑转移患者中快速颅内应答——真实世界病例系列:病例报告

2025-03-240
PRE
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
2025-01-010
PRE
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
2024-12-250
OAAI
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
2024-09-013
OA
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)
2024-08-200
OA